<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE294nnn/GSE294972/</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Mus musculus</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294972</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Clofazimine induced changes in the host immune system</name><description>Clofazimine (CLO), an antibiotic drug has been in use as such for more than 50 years to treat Mycobacterium leprosae and MDR Mycobacterium tuberculosis infections in humans. Long suspected and proven during the COVID pandemic the drug also has a secondary function as a modulator of the host immune system. We want to measure changes in the transcriptome of cells (bulk RNAseq) treated with CLO at t=6h where we see the onset of phenotypic changes in these cells without the typical cell death induced at higher CLO concentrations over a longer period of time.</description><dates><publication>2026/04/22</publication></dates><accession>GSE294972</accession><cross_references><GSM>GSM8934301</GSM><GSM>GSM8934300</GSM><GSM>GSM8934311</GSM><GSM>GSM8934303</GSM><GSM>GSM8934302</GSM><GSM>GSM8934304</GSM><GSM>GSM8934307</GSM><GSM>GSM8934306</GSM><GSM>GSM8934309</GSM><GSM>GSM8934308</GSM><GSM>GSM8934310</GSM><GSM>GSM8934299</GSM><GPL>34328</GPL><GSE>294972</GSE><taxon>Mus musculus</taxon></cross_references></HashMap>